Levallois-Perret, France-based Cardiawave develops its Valvosoft NIUT device for the treatment of severe symptomatic calcific aortic stenosis.
As CEO, Pierron holds responsibility for overseeing the deployment of Valvosoft in the European market and U.S. clinical trials. He also expects to strengthen strategic partnerships and lead the company’s Series B funding round. Cardiawave has its CE mark application submitted and a pivotal study of 60 patients underway, with enrollment completed.
Pierron brings more than 25 years of experience in cardiovascular therapies. Before joining Cardiawave, he held executive roles at “well-known companies in the sector,” the company said in a news release. He brings international experience and expertise in development, acquisitions and IPO transactions, the company said.
“The approach developed by Cardiawave is unique and complements the existing range of cardiology treatments,” Pierron said. “Being entirely non-invasive, it expands the treatment options of patients suffering from severe symptomatic aortic valve stenosis. I am very honored to be joining this visionary team and to be working with them to bring this disruptive solution to market, in order to treat the largest number of people as quickly as possible. Cardiawave’s technology represents a major step forward, one that is acknowledged by the international medical community, and our clinical results are very promising. I am determined to make this innovation a success in our various markets.”
